Moderna’s stock has rallied on hantavirus research that is ‘early-stage’ in nature

🇺🇸 MarketWatch (US) —

AI Summary

Moderna is currently working on an early-stage hantavirus vaccine in collaboration with the U.S. Army and a research center in Korea. This research has led to a positive response in the stock market regarding the company's prospects.

The biotech company has a pre-clinical program with the U.S. Army and a vaccine center at a Korean university.

Markets Health Moderna hantavirus vaccine U.S. Army biotech stock market

Read original source →